Zhao Haosen, Chen Shurui, Lin Sen, Mei Xifan
Department of Orthopaedic Rehabilitation, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, 121000, P. R. China.
Cardiac Intensive Care Unit, Cardiovascular Hospital, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong Province, 510317, P. R. China.
Regen Biomater. 2024 Jul 17;11:rbae087. doi: 10.1093/rb/rbae087. eCollection 2024.
The treatment of peripheral neuropathy resulting from diabetes primarily emphasizes neurotrophic medications. However, a growing body of clinical studies indicates that neuroinflammation plays a significant role in the pathogenesis of neuropathic pain. This has spurred active exploration of treatment strategies leveraging nanomedicine for diseases, aiming for superior therapeutic outcomes. In this context, we have developed biodegradable nanoparticles made of polylactic-co-glycolic acid, loaded with triptolide (pCel), designed to alleviate somatic cell neuropathic pain induced by diabetes. Treatment with pCel notably reduced levels of reactive oxygen species and apoptosis . Furthermore, the progression of streptozotocin-induced diabetes, characterized by elevated renal function indices (blood urea nitrogen, creatinine), liver function indices (bilirubin, alkaline phosphatase) and decreased levels of albumin and globulin, was mitigated following pCel administration. Importantly, oral treatment with pCel significantly inhibited mechanical allodynia and the activation of the sciatic glial cells in diabetic rats. These findings indicate that this synthetic, biodegradable nanomedicine exhibits excellent stability, biocompatibility and catalytic activity, making it a promising and innovative approach for the management of chronic pain conditions associated with diabetic neuropathy.
糖尿病所致周围神经病变的治疗主要侧重于神经营养药物。然而，越来越多的临床研究表明，神经炎症在神经性疼痛的发病机制中起重要作用。这激发了人们积极探索利用纳米医学治疗疾病的策略，以期获得更好的治疗效果。在此背景下，我们研发了由聚乳酸 - 乙醇酸共聚物制成的可生物降解纳米颗粒，其负载雷公藤内酯醇（pCel），旨在减轻糖尿病诱导的体细胞神经性疼痛。pCel治疗显著降低了活性氧水平和细胞凋亡。此外，链脲佐菌素诱导的糖尿病进展（表现为肾功能指标（血尿素氮、肌酐）升高、肝功能指标（胆红素、碱性磷酸酶）升高以及白蛋白和球蛋白水平降低）在给予pCel后得到缓解。重要的是，pCel口服治疗显著抑制了糖尿病大鼠的机械性异常性疼痛和坐骨神经胶质细胞的激活。这些发现表明，这种合成的、可生物降解的纳米药物具有出色的稳定性、生物相容性和催化活性，使其成为治疗与糖尿病神经病变相关慢性疼痛病症的一种有前景的创新方法。
